Dr. Faith E. Davies, MD

Dr. Davies practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Davies' NPI, 1487053484, was assigned on August 15, 2014. Dr. Davies graduated from The University of Wales College of Medicine in 1992. Dr. Davies holds New York license 310568.

Dr. Davies' primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Davies' primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Davies is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Davies to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Davies practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Davies' primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Davies is licensed in New York.

CMS data shows 428 Medicare services from Dr. Davies across 4 procedure codes in 2024, for 195 Medicare patients. Medicare paid $31,071 for them.

CMS counts 195 Medicare patients who saw Dr. Davies in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Davies' median patient age at 72, with 54% women.

In 2024, Dr. Davies wrote 186 Medicare Part D claims for 39 patients. 80% of them were for generic drugs. CMS names the drug for 82 of them, across 4 drugs with 11 or more claims each, at $235,155 in total drug cost. In 2023, CMS named 42 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Davies for performance year 2024, reported as part of a group. Dr. Davies accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Davies as offering telehealth.

Dmand AI links 258 papers to Dr. Davies, published from 2010 to 2025. 2018 was the busiest year, with 24. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Thalidomide. Dr. Davies has published most often in Blood. Dr. Davies' most frequent co-authors are Gareth J. Morgan, MD, Maurizio Zangari, MD and Bart Barlogie, MD.

Dmand AI links Dr. Davies to 8 clinical trials, 7 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Neoplasms, Plasma Cell. University of Arkansas sponsors the most, 7.

CMS Open Payments shows 273 general payments to Dr. Davies from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $115,981. It also lists 2 research payments totaling $18,253 from 2016 to 2018.

Dr. Davies graduated from The University of Wales College of Medicine in 1992.